

Form PTO 1449 (Modified)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	DOCKET NO. 3802-123-27	SERIAL NO. 10/824,796
LIST OF REFERENCES CITED BY APPLICANT (Use Several Sheets if Necessary)		APPLICANT Michael KADAN, et al.	
		FILING DATE April 14, 2004	GROUP ART UNIT 1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
BLi	AA	2001/0053352	12/20/01	YU et al.	—	—	
	AB	5,689,433	12/16/97	KISTNER et al.	—	—	
	AC	5,871,726	02/16/99	HENDERSON et al.	—	—	
	AD	5,998,205	12/07/99	HALLENBECK et al.	—	—	
↓	AE	6,432,700	08/13/02	HENDERSON et al.	—	—	

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
	AF				
	AG				
	AH				
	AI				
	AJ				

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

BLi	AP	Wu, et al., "Incorporation of Adenovirus into a Ligand-based DNA Carrier System Results in Retention of Original Receptor Specificity and Enhances Targeted Gene Expression", Journal of Biological Chemistry, Vol. 269, No. 15, pp. 11542-1546, 1994.
	AQ	Sato, et al., "Enhanced and Specific Gene Expression via Tissue-Specific Production of Cre Recombinase Using Adenovirus Vector", Biochemical and Biophysical Research Communications, Vol. 244, pp. 455-462, 1998.
	AR	American Type Culture Collection (ATTC) Website, ATTC Number CCE - 2.2, Designation HeLa S3, 2004.
	AS	Gorziglia, et al., "Generation of an Adenovirus Vector Lacking E1, E2a, E3, and All of E4 except Open Reading Frame 3", Vol. 73, No. 7, Journal of Virology, pp. 6048-6055, 1999.
↓	AT	Burger, et al., "Local and systemic effects after adenoviral transfer of the murine granulocyte-macrophage colony-stimulating factor gene into mice", British Journal of Haematology, Vol. 108, pp. 641-652, 2000.

EXAMINER	BLi	DATE CONSIDERED 02/15/2006
----------	-----	----------------------------

*EXAMINER: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



EV519865651US

PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/824,796
(use as many sheets as necessary)				Filing Date	April 14, 2004
Sheet	1	of	5	First Named Inventor	KADAN, MICHAEL
				Art Unit	1646
				Examiner Name	N/A
				Attorney Docket Number	GTIN-007

U.S. PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Document Number		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ³ (if known)	Publication Date MM-DD-YYYY		
B2i		US- 5677178	10-14-1997	McCormick, F.	
		US- 5698443	12-16-1997	Henderson	
		US- 5770442	06-23-1998	Wickham	
		US- 5801029	09-01-1998	McCormick, F.	
		US- 5830686	11-03-1998	Henderson	
		US- 5891690	11-30-1999	Massie	
		US- 5994128	11-30-1999	Fallaux	
		US- 5998205	12-07-1999	Hallenbeck	
		US- 6033908	03-07-2000	Bout	
		US- 6365394	04-02-2002	Gao	
		US- 6432700	08-20-2002	Henderson	
		US- 6436394	08-20-2002	Henderson	
		US- 6495130	12-17-2002	Henderson	
		US- 6551587	04-22-2003	Hallenbeck	
		US- 6585968	07-01-2003	Little	
		US- 6638762	10-28-2003	Chang	
		US- 6676935	01-13-2004	Henderson	
		US- 6692736	02-17-2004	Yu	
		US- 20010053352	12-20-2001	Yu	
		US- 20020120117	08-29-2002	Zhang	
		US- 20020136707	09-26-2002	Yu	
		US- 20020192187	12-19-2002	McClelland	
		US- 20030026792	02-06-2003	Lamparsky	
		US- 20030068307	04-10-2003	Yu	
		US- 20030152553	08-14-2003	Henderson	
		US- 20030039633	02-27-2003	Yu	
		US- 20030104625	06-05-2003	Cheng/Ennist	

FOREIGN PATENT DOCUMENTS					
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document		Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY		

Examiner Signature	B2i	Date Considered	02/15/2006
--------------------	-----	-----------------	------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 2 Applicant's unique citation designation number (optional). 3 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<p>Substitute for form 1449B/PTO</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> <p>(use as many sheets as necessary)</p>				Complete if Known	
				Application Number	10/824,796
				Filing Date	April 14, 2004
				First Named Inventor	KADAN, MICHAEL
				Group Art Unit	1646
Examiner Name					
Sheet	2	of	5	Attorney Docket Number	GTIN-007

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
BLI		WO 00/15820	03-23-2000	YU		
		WO 02/067861	09-08-2000	CHENG		
		WO 02/068627	09-06-2002	GORZIGLIA		
		WO 03/07859	01-30-2003	YU		
		WO 03/104476	12-18-2003	BOWE		
		WO 04/042025	05-21-2004	YU		
		WO 92/03563	03-05-1992	GLAZENRUR		
		WO 95/19434	07-20-1995	HENDERSO		
		WO 95/34671	12-21-1995	KOVESDI		
		WO 96/17053	06-06-1996	HALLENREC		
		WO 96/18418	06-20-1996	KADAN		
		WO 98/13499	04-02-1998	NEMERROW		
		WO 98/39464	09-11-1998	HFNDERSO		
		WO 98/39465	09-11-1998	LITTI F		
		WO 98/39466	09-11-1998	YU		
		WO 98/39467	09-11-1998	LAMPARSKY		
		WO 99/06576	02-11-1999	YU		
		WO 99/25860	05-27-1999	CHANG		

OTHER ART—NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher city and/or country where published				T ²
BLI		BLACKWOOD et al., GOING THE DISTANCE: A CURRENT VIEW OF ENHANCER ACTION, Science, 1998, 281:60-63				
BLI		DORONIN et al., TUMOR-SPECIFIC, REPLICATION-COMPETENT ADENOVIRUS VECTORS OVEREXPRESSING THE ADENOVIRUS DEATH PROTEIN, Journal of Virology, 2000, 74(13):6147-6155				
BLI		DORONIN et al., TISSUE-SPECIFIC, TUMOR-SELECTIVE, REPLICATION-COMPETENT ADENOVIRUS VECTOR FOR CANCER GENE THERAPY, Journal of Virology, 2001, 75(7):3314-3324				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BLI 02/15/2006

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <small>(use as many sheets as necessary)</small>				Complete if Known	
Sheet	3	of	5	Attorney Docket Number	GTIN-007

OTHER ART—NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), <small>whether it is an abstract or full article</small>			T ²
BZI		DORONIN et al., OVEREXPRESSION OF THE ADP (E3-11.6K) PROTEIN INCREASES CELL LYSIS AND SPREAD OF ADENOVIRUS, Virology, 2003, Jan 20;305(2):378-87.			
		FALLAUX et al., NEW HELPER CELLS AND MATCHED EARLY REGION 1-DELETED ADENOVIRUS VECTORS PREVENT GENERATION OF REPLICATION-COMPETENT ADENOVIRUSES, Human Gene Therapy, 1998, 9:1909-1917			
		GRAHAM et al., CHARACTERISTICS OF A HUMAN CELL LINE TRANSFORMED BY DNA FROM HUMAN ADENOVIRUS TYPE 5, J. Gen. Virol., 1977, 36:59-72			
		HABIB et al., E1B-DELETED ADENOVIRUS (d1520) GENE THERAPY FOR PATIENTS WITH PRIMARY AND SECONDARY LIVER TUMORS, Human Gene Therapy, 2001, 12:219-226			
		HeLa-S3 -ATCC number CCL-2.2			
		JAKUBCZAK et al., CONSTRUCTION AND CHARACTERIZATION OF ONCOLYTIC ADENOVIRUSES, Molecular Therapy, 2001, 3(5):Abstract 442			
✓		KIM et al., DEVELOPMENT OF A PACKAGING CELL LINE FOR PROPAGATION OF REPLICATION-DEFICIENT ADENOVIRUS VECTOR, Exp. Mol. Med., 2001, 33(3)145-9			

Examiner Signature	BZI	Date Considered	02/15/2005
--------------------	-----	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/824,796
				Filing Date	April 14, 2004
				First Named Inventor	KADAN, MICHAEL
				Group Art Unit	1646
				Examiner Name	
Sheet	4	of	5	Attorney Docket Number	GTIN-007

OTHER ART—NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), and/or where published				T ²
BLI		KRUYT et al., TOWARD A NEW GENERATION OF CONDITIONALLY REPLICATING ADENOVIRUSES: PAIRING TUMOR SELECTIVITY WITH MAXIMAL ONCOLYSIS, Human Gene Therapy, 2002, 13(4):485-495				
		KWONG et al., COMBINATION THERAPY WITH SUICIDE AND CYTOKINE GENES FOR HEPATIC METASTASES OF LUNG CANCER, Chest, 1997, 112(5):1332-1337				
		NEMUNAITIS et al., SELECTIVE REPLICATION AND ONCOLYSIS IN p53 MUTANT TUMORS WITH ONYX-015, AN E1B-55Kd GENE-DELETED ADENOVIRUS, IN PATIENTS WITH ADVANCED HEAD AND NECK CANCER: A PHASE II TRIAL, Cancer Research, 2000, 60:6359-6366				
		RUSSELL, UPDATE ON ADENOVIRUS AND ITS VECTORS, Journal of General Virology, 2000, 81:2573-2604				
		SAUTHOFF et al., DELETION OF THE ADENOVIRAL E1b-19Kd GENE ENHANCES TUMOR CELL KILLING OF A REPLICATING ADENOVIRAL VECTOR, Human Gene Therapy, 2000, 11:379-388				
↓		SCHIEDNER et al., EFFICIENT TRANSFORMATION OF PRIMARY HUMAN AMNIOCYTES BY E1 FUNCTIONS OF Ad5: GENERATION OF NEW CELL LINES FOR ADENOVIRAL VECTOR PRODUCTION, 2002, Human Gene Therapy, 11:2105-2116				

Examiner Signature	BLI	Date Considered	02/15/2005
--------------------	-----	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
Sheet	5	of	5	Application Number	10/824,796
				Filing Date	April 14, 2004
				First Named Inventor	KADAN, MICHAEL
				Group Art Unit	1646
				Examiner Name	
				Attorney Docket Number	GTIN-007

OTHER ART—NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), <small>with other cities and/or countries where published</small>	T ²

BC:	SMITH et al., TRANSCRIPTIONAL REGULATION OF MAMMALIAN GENES IN VIVO, 1997, J. Biol. Chem. 272:27493-27496	
	STEINWAERDER et al., INSULATION FROM VIRAL TRANSCRIPTIONAL REGULATORY ELEMENTS IMPROVES INDUCIBLE TRANSGENE EXPRESSION FROM ADENOVIRUS VECTORS IN VITRO AND IN VIVO, Gene Therapy, 2000, 7(7):556-567	
↓	YU et al., SELECTIVELY REPLICATING ONCOLYTIC ADENOVIRUSES AS CANCER THERAPEUTICS, Current Opinion in Molecular Therapeutics, 2002, 4(5), pp: 435-443	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

BLI 02/15/0026